Binocular Processing, a California-based startup that is developing augmented reality devices and building an augmented reality ecosystem, is currently focusing on applying video processing to help low vision patients in the $40 billion visual care market.
Its currently-developed augmented reality ecosystem platform, dual-lens augmented reality glasses, uses breakthrough technology to develop the complexity of relocating video pixels from blurred visual areas to adjacent areas with viable visual acuity for patients with macular degeneration in patients with macular degeneration. The algorithm, whose technology has been registered with US patents, is the first solution to provide advanced central vision defects in patients with retinal disease, and patients with macular degeneration or other irreversible central eye defects can manipulate visual perception to restore functional vision.
The binocular processing R&D team further explained that its technology mimics the ability of the brain to overcome the natural blind spots in the vision, using other collected visual information to fill the patient's desired field of view, clinically the wearer's retinal field of view is drawn, and then the camera projects a Display real-world video images. However, the image is not transmitted to the defective area, but the video is displayed to an area where the function remains in the macula or the peripheral retina. The projection area can also be adjusted during disease progression during control using the augmented reality device.
The remaining related hardware information is as follows, weighing less than 200 grams, 110 degree field of view with 2.5K resolution, 2 HD cameras, 5 cameras/sensors, including noise canceling microphone and stereo, Bluetooth and WiFi wireless connection and built-in battery.
The Eyes Treatment team believes that its innovative augmented reality device brings new hopes of regaining functional vision that was previously thought impossible, the impact on patient quality of life and the ability to maintain or restore work in the home and workplace. The ability will be immeasurable. In addition to the medical industry , the company plans to extend its platform to other areas, including gaming, commercial, industrial, haze, e-commerce, aerospace, drone and defense.
Disclaimer: This article is not a medical diagnosis recommendation or an eye health information recommendation
In vivo, the target protein and E3 enzyme can be brought close together, so that the target protein is tagged with ubiquitin and then degraded through the ubiquitin-proteasome pathway.In vivo, PROTAC uses the ubiquitin-proteasome pathway to degrade target proteins. The specific process is as follows: The ligands at both ends of PROTAC recognize E3 ubiquitin ligase and target protein respectively, forming a triple complex of target protein-PROTAC-E3 ligase. It brings the target protein and E3 ligase closer together, and then transfers ubiquitin to the target protein. The proteasome accepts the ubiquitin-tagged protein and cuts it into short peptides composed of 7 to 9 amino acids. After the target protein is degraded, PROTAC molecules can be released to participate in the degradation process of the next protein. Therefore, this degradation has a catalytic effect, and efficient degradation can be achieved with a smaller drug dose.
Different from the mechanism of action of traditional small molecule inhibitors, which inhibit the function of the target protein by binding to the active site of the target protein, PROTAC molecules directly degrade the target protein to achieve disease treatment effects. Compared with it, PROTAC has many advantages:
1. Target point
Traditional small molecule inhibitors need to act on the active site of the target protein to inhibit its function. This target protein accounts for less than 20% of disease-related proteins, while PROTAC technology only needs to connect the target protein to E3 ubiquitin. The enzyme is brought closer to degrade the substrate protein, which can be applied to undruggable targets such as some transcription factors.
2. Catalytic protein degradation function
Small molecule inhibitors act on the target protein to inhibit its activity but cannot degrade it; while PROTAC molecules can directly catalyze the degradation of the target protein.
3. Overcoming drug resistance
After small molecule inhibitors act on the target protein, they may cause overexpression or mutation of the target protein, thereby causing drug resistance, causing the small molecule inhibitor to lose its inhibitory function on the target protein; and PROTAC molecules degrade the target protein through the proteasome pathway , which can avoid drug resistance due to point mutations to a certain extent.
4. High selectivity
Due to the synergy between target proteins and E3 ubiquitin ligases, PROTAC molecules can improve their selectivity based on small molecule inhibitors. Low dosage and low toxicity. PROTAC molecules can directly catalyze the degradation of the target protein, and after the target protein is degraded, it can be released to participate in the degradation process of the next protein, achieving significant and long-lasting pharmacological effects under low-dose conditions.
The PROTAC related intermediate derivatives we develop mainly include:
1. Benzene ring mono substituted CRBN derivatives, such as
3-(6-Amino-1-oxo-isoindolin-2-yl)piperidine-2,6-dione Cas 191732-74-8
3-(4-iodo-1-oxoisoindolin-2-yl)piperidine-2,6-dione cas 2207541-30-6
2. Benzene ring disubstituted CRBN derivatives, such as
2-(2,6-Dioxopiperidin-3-yl)-4,5-difluoroisoindoline-1,3-dione 2222115-19-5
3-(5-Bromo-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione 2408391-89-7
3. Other CRBN derivatives, such as
2616553-35-4
1-(4-(Piperidin-4-yl)phenyl)dihydropyrimidine-2,4(1H,3H)-dione hydrochloride
2446913-99-9
4. Linkers
2,7-Diazaspiro[3.5]nonane-2-carboxylic acid,7-(4-piperidinylmethyl)-, 1,1-dimethylethyl ester 2894098-28-1
1-BOC-4-(4-AMINOBUTYL)PIPERAZINE 745048-07-1
Benzene Ring Mono Substituted CRBN Derivatives;Benzene Ring Disubstituted CRBN Derivatives;Benzene Ring Disubstituted CRBN Derivatives
Taizhou Volsen Chemical Co., Ltd. , https://www.volsenchem.com